Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

Crizotinib, the first clinically designed and synthesized as a tyrosine kinase inhibitor targeting mesenchymal–epithelial transition factor, indicating marked anticancer activity in patients with advanced, anaplastic lymphoma kinase-positive non-small-cell lung cancer, was approved by the US Food an...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Liting, Zhang, Haijun, Shao, Weiwei, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599072/
https://www.ncbi.nlm.nih.gov/pubmed/26491259
http://dx.doi.org/10.2147/DDDT.S91988
_version_ 1782394179441131520
author Guo, Liting
Zhang, Haijun
Shao, Weiwei
Chen, Baoan
author_facet Guo, Liting
Zhang, Haijun
Shao, Weiwei
Chen, Baoan
author_sort Guo, Liting
collection PubMed
description Crizotinib, the first clinically designed and synthesized as a tyrosine kinase inhibitor targeting mesenchymal–epithelial transition factor, indicating marked anticancer activity in patients with advanced, anaplastic lymphoma kinase-positive non-small-cell lung cancer, was approved by the US Food and Drug Administration in 2011. In this review, we focus on the efficacy of crizotinib compared with chemotherapy in advanced anaplastic lymphoma kinase-positive lung cancer and present the role of crizotinib as a personalized alternative in previously treated patients with non-small-cell lung cancer.
format Online
Article
Text
id pubmed-4599072
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45990722015-10-21 Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer Guo, Liting Zhang, Haijun Shao, Weiwei Chen, Baoan Drug Des Devel Ther Review Crizotinib, the first clinically designed and synthesized as a tyrosine kinase inhibitor targeting mesenchymal–epithelial transition factor, indicating marked anticancer activity in patients with advanced, anaplastic lymphoma kinase-positive non-small-cell lung cancer, was approved by the US Food and Drug Administration in 2011. In this review, we focus on the efficacy of crizotinib compared with chemotherapy in advanced anaplastic lymphoma kinase-positive lung cancer and present the role of crizotinib as a personalized alternative in previously treated patients with non-small-cell lung cancer. Dove Medical Press 2015-10-03 /pmc/articles/PMC4599072/ /pubmed/26491259 http://dx.doi.org/10.2147/DDDT.S91988 Text en © 2015 Guo et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Guo, Liting
Zhang, Haijun
Shao, Weiwei
Chen, Baoan
Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
title Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
title_full Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
title_fullStr Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
title_full_unstemmed Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
title_short Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
title_sort crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599072/
https://www.ncbi.nlm.nih.gov/pubmed/26491259
http://dx.doi.org/10.2147/DDDT.S91988
work_keys_str_mv AT guoliting crizotinibasapersonalizedalternativefortargetedanaplasticlymphomakinaserearrangementinpreviouslytreatedpatientswithnonsmallcelllungcancer
AT zhanghaijun crizotinibasapersonalizedalternativefortargetedanaplasticlymphomakinaserearrangementinpreviouslytreatedpatientswithnonsmallcelllungcancer
AT shaoweiwei crizotinibasapersonalizedalternativefortargetedanaplasticlymphomakinaserearrangementinpreviouslytreatedpatientswithnonsmallcelllungcancer
AT chenbaoan crizotinibasapersonalizedalternativefortargetedanaplasticlymphomakinaserearrangementinpreviouslytreatedpatientswithnonsmallcelllungcancer

Ejemplares similares